See other indications for REVLIMID:

This website is intended for U.S. Healthcare Professionals.

Indication Prescribing Information

This website is intended for U.S. Healthcare Professionals.

REVLIMID is indicated for the treatment of adult patients with mantle cell lymphoma (MCL) whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib. REVLIMID is not indicated and is not recommended for the treatment of patients with chronic lymphocytic leukemia (CLL) outside of controlled clinical trials.

  • Home
  • Access & Resources

Bristol Myers Squibb is committed to providing support for patients who are prescribed REVLIMID

Bristol Myers Squibb offers a number of resources that may be helpful for you, your office, and your patients in getting access to REVLIMID, including the Lenalidomide Risk Evaluation and Mitigation Strategy (REMS) program and BMS Access Support®. Click on the program offerings below to find out more.

Hypothetical REVLIMID® Patient and Healthcare Provider
Hypothetical REVLIMID® Patient and Healthcare Provider

Explore these resources for HCPs and their patients with MCL.

View Resources

REVLIMID is only available through a restricted distribution program called the Lenalidomide REMS program.1

Learn About Lenalidomide REMS
HCP Looking into a Microscope
HCP Looking into a Microscope
HCP Discussing REVLIMID® Resources with Hypothetical Patient
HCP Discussing REVLIMID® Resources with Hypothetical Patient

REVLIMID is only available through a select network of specialty pharmacies.

See Specialty Pharmacy Network